Research dossier

Melanotan II — non-selective α-MSH analogue dossier

A cyclic α-MSH analogue, non-selective between melanocortin receptor subtypes.

6 min read · Purpeptide Research Desk ·

Translated from the French original, which remains the reference version: lire en français →

Melanotan II — research dossier illustration

Molecular identity

ParameterValue
CAS number121062-08-6
Molar mass1024.18 g/mol
Molecular formulaC₅₀H₆₉N₁₅O₉
Sequence / natureAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
Purity≥99%
AppearanceWhite lyophilised powder

The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.

Research context

A compound frequently cited as an example of the limits of a non-selective tool: its activity at several subtypes makes it a poor instrument for mechanistic dissection, even as it remains widely used. The health-vigilance context surrounding it calls for particular rigour in how it is presented.

Mechanism studied

Melanotan II is a cyclic heptapeptide analogue of α-MSH (alpha-melanocyte stimulating hormone). Cyclisation by a lactam bridge and the presence of non-natural residues — including a D-configuration tryptophan — stabilise it strongly relative to the native peptide, which is rapidly degraded.

Its principal pharmacological feature, widely documented, is the absence of selectivity between subtypes: it activates several melanocortin receptors, notably MC1R and MC4R, with affinities of the same order of magnitude. That non-selectivity limits its usefulness as a pharmacological probe — an observed effect cannot be attributed to a particular subtype without a selective antagonist as a control.

The published in-vitro work concerns cAMP accumulation assays in cell lines expressing each subtype, and melanogenesis measurements in melanocyte cultures, with quantification of the melanin produced.

This compound is also the subject of vigilance communications issued by several European health authorities; that regulatory context is noted here for information and reinforces the strictly laboratory framing of this material.

In-vitro literature

The reference assays use HEK293 lines expressing each recombinant human subtype. Melanogenesis measurements in primary melanocytes are more variable between laboratories.

Bibliographic entry points

These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.

Distinguishing this compound from its analogues

To be distinguished from PT-141, its deamidated metabolite, and from afamelanotide, a linear analogue with a different profile.

The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.

Methodological limits

Non-selectivity between subtypes is the defining limit: without a selective antagonist as a control, no observed effect can be attributed to a particular receptor. This compound is also the subject of vigilance communications from several European health authorities, a context that reinforces the strictly laboratory framing of its use.

These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.

Analytical parameters

Cyclisation by a lactam bridge and non-natural residues. Mass confirmation and verification of the ring are indispensable.

ParameterValue
StorageStore at −20 °C, protected from light
SolubilitySoluble in bacteriostatic water (BAC)
StabilityStable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C
Control methodsRP-HPLC · MS · NMR

Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.

Resulting concentrations

The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.

Format1 ml2 ml3 ml
10mg10.00 mg/ml5.00 mg/ml3.33 mg/ml

These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.

Protocol design

Three points govern the validity of an assay using this material, whatever the question being asked.

The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.

The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.

The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.

Lot verification

The following formats are covered by a Janoshik Analytical report, readable from the product page:

  • 10mg — lot report available
FormatLot reportAvailability
10mgCoveredIn stock

The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.

Frequently asked questions

How does this product arrive?

As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.

Which solvent should be used for reconstitution?

Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.

How long does the material remain stable?

The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.

Does the analysis report correspond exactly to my vial?

The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.

Can this product be used on humans or animals?

No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.

See also: Melanotan II or PT-141: the comparison

Dossiers in the same category

Related dossiers

All research dossiers → · Catalogue → · Glossary →